- Home
- ALZN vs BMRA Comparison
ALZN vs BMRA Comparison
Compare ALZN & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- BMRA
- Stock Information
- Founded
- ALZN 2016
- BMRA 1971
- Country
- ALZN United States
- BMRA United States
- Employees
- ALZN N/A
- BMRA N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ALZN Health Care
- BMRA Health Care
- Exchange
- ALZN Nasdaq
- BMRA Nasdaq
- Market Cap
- ALZN 8.2M
- BMRA 8.2M
- IPO Year
- ALZN 2021
- BMRA N/A
- Fundamental
- Price
- ALZN $2.53
- BMRA N/A
- Analyst Decision
- ALZN Strong Buy
- BMRA
- Analyst Count
- ALZN 1
- BMRA 0
- Target Price
- ALZN $42.00
- BMRA N/A
- AVG Volume (30 Days)
- ALZN 170.2K
- BMRA 33.1K
- Earning Date
- ALZN 09-10-2025
- BMRA 10-10-2025
- Dividend Yield
- ALZN N/A
- BMRA N/A
- EPS Growth
- ALZN N/A
- BMRA N/A
- EPS
- ALZN N/A
- BMRA N/A
- Revenue
- ALZN N/A
- BMRA $5,311,000.00
- Revenue This Year
- ALZN N/A
- BMRA N/A
- Revenue Next Year
- ALZN N/A
- BMRA N/A
- P/E Ratio
- ALZN N/A
- BMRA N/A
- Revenue Growth
- ALZN N/A
- BMRA N/A
- 52 Week Low
- ALZN $2.06
- BMRA $2.08
- 52 Week High
- ALZN $17.10
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- ALZN 52.36
- BMRA N/A
- Support Level
- ALZN $2.33
- BMRA N/A
- Resistance Level
- ALZN $2.55
- BMRA N/A
- Average True Range (ATR)
- ALZN 0.10
- BMRA 0.00
- MACD
- ALZN 0.02
- BMRA 0.00
- Stochastic Oscillator
- ALZN 66.07
- BMRA 0.00
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.